Weekly Insulin Efsitora Alfa vs. Glargine U100 for Type 2 Diabetes | QWINT-4 Trial
- A new once-weekly insulin, efsitora, offers a potential alternative for adults managing type 2 diabetes.
- The findings suggest efsitora is both effective and well-tolerated.
- Further studies may explore the long-term benefits and broader applications of efsitora as a weekly insulin alternative in diabetes management.
Efsitora, a promising new weekly insulin, offers a significant advancement for individuals with type 2 diabetes. This innovative treatment, compared directly with glargine U100, shows similar efficacy in the recent QWINT-4 trial, effectively managing blood sugar levels. This allows for a reduced injection frequency, providing increased convenience for patients. The latest research highlights that efsitora is well-tolerated, signaling a positive step forward in diabetes management. The full details, including the specific findings of the basal and prandial insulin usage, are now available from News Directory 3. Discover what’s next for this groundbreaking weekly insulin alternative.
Weekly Insulin Alternative Shows Promise for Type 2 Diabetes
Updated June 29, 2025
A new once-weekly insulin, efsitora, offers a potential alternative for adults managing type 2 diabetes. Studies indicate that the weekly injection provides comparable blood sugar (HbA1c) reductions to daily basal insulin,specifically glargine U100,when used with basal and prandial insulin.
The findings suggest efsitora is both effective and well-tolerated. It also reduces the number of injections needed, offering a more convenient option for managing type 2 diabetes with insulin therapy.
What’s next
Further studies may explore the long-term benefits and broader applications of efsitora as a weekly insulin alternative in diabetes management.